[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350518-105":59,"doc-detail-350518-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","ceralasertib-monotherapy-in-patients-with-atm-altered-advanced-solid-tumors-or-metastatic-castration-resistant-prostate-cancer-data-from-the-phase-iia-planette-study","Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer - Data from the Phase IIa PLANETTE Study","","Ceralasertib is an oral ATR inhibitor with preclinical activity in ATM-altered cancers. The phase IIa PLANETTE study assessed ceralasertib 160 mg twice daily on days 1 to 14 of 28-day cycles in previously treated advanced solid tumors (cohort A) or metastatic castration-resistant prostate cancer (cohort B) with centrally confirmed ATM alterations. Primary endpoints were ORR (cohort A) and composite response (cohort B), with PFS and safety as secondary outcomes.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ceralasertib-monotherapy-in-patients-with-atm-altered-advanced-solid-tumors-or-metastatic-castration-resistant-prostate-cancer-data-from-the-phase-iia-planette-study/350518/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ceralasertib-monotherapy-in-patients-with-atm-altered-advanced-solid-tumors-or-metastatic-castration-resistant-prostate-cancer-data-from-the-phase-iia-planette-study/350518.png","ImageObject",300,407,{"name":92,"@type":93},"Franzy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What patient groups were included in the phase IIa PLANETTE study?","Question",{"text":112,"@type":113},"The study included previously treated advanced solid tumors (cohort A) and metastatic castration-resistant prostate cancer (cohort B), both enriched for ATM alterations confirmed centrally.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was ceralasertib administered and what were the primary efficacy endpoints?",{"text":117,"@type":113},"Patients received ceralasertib 160 mg twice daily on days 1–14 of a 28-day cycle. Primary endpoints were objective response rate (ORR) for cohort A and composite response rate for cohort B.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key results for response rates and progression-free survival?",{"text":121,"@type":113},"Cohort A ORR was 7.1% with ongoing complete/partial responses, and cohort B composite response rate was 7.7%. Median progression-free survival was 3.7 months in each cohort. Responses in ATM protein loss subgroups were limited.",{"name":123,"@type":110,"acceptedAnswer":124},"What safety findings were reported in the trial?",{"text":125,"@type":113},"Grade ≥3 adverse events occurred in about half of cohort A (50%) and slightly more than half of cohort B (53.3%). Common adverse events included asthenia/fatigue, nausea, and anemia.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},350518,1790241739,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},2336478945519,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-26-0184](https://doi.org/10.1158/2767-9764.CRC-26-0184)  OPEN ACCESS  \nCeralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer:  \nData from the Phase IIa PLANETTE Study  \nRahul Aggarwal1, Antoine Italiano2,3, Susan M. Domchek4, Oscar Goodman5, Sophie Postel-Vinay6,7, Jesus Garcia-Donas8, Tanya Dorff9, Zachery R. Reichert10, Armelle Vinceneux11, Neal Shore12, Catherine H. Marshall13, Joshua Armenia14, Graeme Parr15, Aleksandra Kmieciak16, Natalia Lukashchuk17, Olga Murina17, Daniel Slade18, Neel Shah19, Bienvenu Loemb15, Emma Dean20, Elhan Sanai15, and Wassim Abida21  \n􀀶  \nABSTRACT  \nPurpose: Ceralasertib is an oral ataxia telangiectasia and Rad3–related (ATR) inhibitor with preclinical activity in ataxia-telangiectasia mutated (ATM)-altered cancers. The phase IIa PLANETTE study evaluated ceralasertib in previously treated advanced solid tumors (cohort A) or metastatic castration-resistant prostate cancer (cohort B) with ATM alterations (ATM mutations and/or ATM protein deficiency) .  \nPatients and Methods: Patients received ceralasertib 160 mg twice daily on days 1 to 14 of a 28-day cycle. Efficacy was evaluated in patients with centrally confirmed ATM alterations. The primary endpoint was objective response rate (ORR; cohort A) or composite response rate (CRR: radiographic response, prostate-specific antigen response, or circulating tumor cell conversion; cohort B) . Secondary endpoints included progression-free survival (PFS) and safety.  \nResults: Cohorts A and B included 30 and 15 patients, respectively. ORR (cohort A) was 7. 1%[80% confidence interval (CI), 1.9–17. 9; n ¼ 2/28]: one complete response ongoing at 14.1 months (breast cancer) and one partial response ongoing at 7.4 months (endometrial  \ncancer) . CRR (cohort B) was 7. 7%(80% CI, 0.8–28. 6; n ¼ 1/13) . Inpatients with centrally confirmed ATM protein loss, the ORR was 18. 2%(80% CI, 4.9–41. 5; n ¼ 2/11) and CRR was 0%(80% CI, 0–28; n ¼ 0/7) . The median PFS was 3.7 months in each cohort (cohort A, 80% CI, 1.9–5. 6; cohort B, 80% CI, 1. 9–not calculable) . Grade ≥3 adverse events (AE) occurred in 50% of cohort A and 53. 3% of cohort B patients. The most common AEs overall were asthenia/fatigue, nausea, and anemia.  \nConclusions: Ceralasertib monotherapy was tolerated; however, responses were limited. Alternative patient selection and combination treatments are being explored.  \nSignificance: In the phase IIa PLANETTE study in advanced/metastatic ATM-altered cancers, ceralasertib 160 mg twice daily (days 1–14, 28-day cycle) was tolerated; objective responses were limited, corroborating previous findings with ATR inhibitors in ATM-deficient tumors. Optimizing biomarker-based patient selection beyond ATM deficiency represents a key aspect of future ATR inhibitor development.  \n1Division of Hematology/Oncology, University of California, San Francisco, California. 2Department of Medicine, Institut Bergoni, Bordeaux, France. 3Faculty of Medicine, University of Bordeaux, Bordeaux, France. 4Basser Center for BRCA, University of Pennsylvania, Philadelphia, Pennsylvania. 5Hematology/Oncology, Nevada Oncology Specialists, Las Vegas, Nevada. 6Drug Development Department, U981 INSERM Research Unit, Institut Gustave Roussy, Villejuif, France. 7Cancer Institute, University College of London, London, United Kingdom. 8Gynecologic and Genitourinary Tumors, HM Hospitales – Centro Integral Oncolgico HM Clara Campal, Madrid, Spain. 9Genitourinary Disease Program, City of Hope Comprehensive Cancer Center, Duarte, California. 10University of Michigan, Rogel Comprehensive Cancer Center, Ann Arbor, Michigan. 11Medical Oncology, Centre Lon Brard, Lyon, France. 12START Carolinas/Carolina Urologic Research Center, Myrtle Beach, South Carolina. 13Oncology, Johns Hopkins University, Baltimore, Maryland. 14Oncology Data Science, AstraZeneca, Cambridge, United Kingdom","cbCaiu2svhWFhX0J","https://ap.wps.com/l/cbCaiu2svhWFhX0J","pdf",4049206,11,"English","# Abstract\n## Purpose\n## Patients and Methods\n## Results\n## Conclusions\n## Significance\n# Introduction","[{\"question\":\"What patient groups were included in the phase IIa PLANETTE study?\",\"answer\":\"The study included previously treated advanced solid tumors (cohort A) and metastatic castration-resistant prostate cancer (cohort B), both enriched for ATM alterations confirmed centrally.\"},{\"question\":\"How was ceralasertib administered and what were the primary efficacy endpoints?\",\"answer\":\"Patients received ceralasertib 160 mg twice daily on days 1–14 of a 28-day cycle. Primary endpoints were objective response rate (ORR) for cohort A and composite response rate for cohort B.\"},{\"question\":\"What were the key results for response rates and progression-free survival?\",\"answer\":\"Cohort A ORR was 7.1% with ongoing complete/partial responses, and cohort B composite response rate was 7.7%. Median progression-free survival was 3.7 months in each cohort. Responses in ATM protein loss subgroups were limited.\"},{\"question\":\"What safety findings were reported in the trial?\",\"answer\":\"Grade ≥3 adverse events occurred in about half of cohort A (50%) and slightly more than half of cohort B (53.3%). Common adverse events included asthenia/fatigue, nausea, and anemia.\"}]","Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer - Data from the Phase IIa PLANETTE Study | PDF",1790089388,28,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3ffb3033c2b63f366a25e395bbd423b6.webp",983,1263,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3e0f6e01db5eadd3d530a07c2785897e.webp",982,1262,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7c9a73c47450ccdbde9936db3afe86dd.webp",981,1261,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7f32442a45befd129b076aa371ef39cf.webp",980,1259]